Results 121 to 130 of about 315,728 (345)

Immunogenicity of therapeutic proteins [PDF]

open access: yesNephrology Dialysis Transplantation, 2003
The use of proteins for medical applications has revolutionized therapies of many diseases/disorders that were often incurable with small-molecule medicines. However, since the first use of proteins as medicines, their immunogenicity has been a major problem.
openaire   +4 more sources

H2O2‐Generating Advanced Nanomaterials for Cancer Treatment

open access: yesAdvanced Functional Materials, EarlyView.
H2O2‐generating nanoplatforms can exploit tumor redox imbalance for O2 and toxic reactive oxygen species generation, leading to hypoxia reversal, and apoptosis of cancer cells, respectively. This review highlights the mechanisms of these nanoplatforms, including exogenous H₂O₂ delivery, endogenous amplification, and metal peroxides, which leads to ...
Kiyan Musaie   +8 more
wiley   +1 more source

Virus-Like Particle, Liposome, and Polymeric Particle-Based Vaccines against HIV-1

open access: yesFrontiers in Immunology, 2018
It is acknowledged that vaccines remain the best hope for eliminating the HIV-1 epidemic. However, the failure to produce effective vaccine immunogens and the inability of conventional delivery strategies to elicit the desired immune responses remains a ...
Yong Gao   +2 more
doaj   +1 more source

Alleviation of Aging‐Related Hallmarks in a Mouse Model of Progeria via a Nanoparticle‐Based Artificial Transcription Factor

open access: yesAdvanced Functional Materials, EarlyView.
Oct4‐nanoscript, a biomimetic nanoparticle‐based artificial transcription factor, precisely regulates cellular rejuvenation by activating Oct4 target genes, restoring epigenetic marks, and reducing DNA damage. In a progeria model, it effectively rescued aging‐associated pathologies and extended lifespan.
Hongwon Kim   +8 more
wiley   +1 more source

Complex immunogenicity assessment in caplacizumab-treated patients with immune-mediated thrombotic thrombocytopenic purpura who have received plasma exchange

open access: yesResearch and Practice in Thrombosis and Haemostasis
Background: International Society on Thrombosis and Haemostasis guidelines for immune-mediated thrombotic thrombocytopenic purpura (iTTP) treatment recommend concurrent therapeutic plasma exchange (TPE), immunosuppressive therapy (IST), and caplacizumab.
Brendy Van Butsel   +6 more
doaj  

Intraoral Drug Delivery: Bridging the Gap Between Academic Research and Industrial Innovations

open access: yesAdvanced Functional Materials, EarlyView.
Intraoral drug delivery offers a promising route for systemic and localized therapies, yet challenges such as enzymatic degradation, limited permeability, and microbial interactions hinder efficacy. This figure highlights innovative strategies—mucoadhesive materials, enzyme inhibitors, and permeation enhancers—to overcome these barriers.
Soheil Haddadzadegan   +4 more
wiley   +1 more source

Griffithsin: An Antiviral Lectin with Outstanding Therapeutic Potential

open access: yesViruses, 2016
Griffithsin (GRFT), an algae-derived lectin, is one of the most potent viral entry inhibitors discovered to date. It is currently being developed as a microbicide with broad-spectrum activity against several enveloped viruses.
Sabrina Lusvarghi, Carole A. Bewley
doaj   +1 more source

Bacteria‐Derived Extracellular Vesicle as A “Trojan Horse” for Selective M1 Macrophage‐Targeting in A Multi‐Cellular Entanglement Environment

open access: yesAdvanced Functional Materials, EarlyView.
The temporary transition of macrophages from a pro‐inflammatory phenotype of macrophages (M1) to an anti‐inflammatory phenotype of macrophages (M2) is crucial for tissue repair and regeneration processes. Bacterial outer membrane vesicles (OMVs) are utilized as a “trojan horse” for specific M1 macrophage‐targeting and anti‐inflammatory drug delivery ...
Donglin Cai   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy